{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+warfarin",
    "query": {
      "intervention": "placebo warfarin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+warfarin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T04:52:30.349Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00329238",
      "title": "Secondary Prevention of Venous Thrombo Embolism (VTE).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2867,
      "start_date": "2006-05",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-19",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 18,
      "location_summary": "Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00329238"
    },
    {
      "nct_id": "NCT01250535",
      "title": "Human Cytochrome P450 4F Enzymes and Drug Interactions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Drug Drug Interactions"
      ],
      "interventions": [
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lovastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 19,
      "start_date": "2010-12",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-21",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250535"
    },
    {
      "nct_id": "NCT01561937",
      "title": "Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Haemostasis",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2007-01",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-25",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561937"
    },
    {
      "nct_id": "NCT00580216",
      "title": "Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Idrabiotaparinux sodium",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for idrabiotaparinux)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for warfarin)",
          "type": "DRUG"
        },
        {
          "name": "Avidin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for avidin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3773,
      "start_date": "2007-12",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 162,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mountain Home",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580216"
    },
    {
      "nct_id": "NCT01036802",
      "title": "Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2009-12",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2016-05-09",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01036802"
    },
    {
      "nct_id": "NCT02836652",
      "title": "Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "HeartMate II (HMII)",
          "type": "DEVICE"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "acetylsalicylic acid (ASA) therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2016-11",
      "completion_date": "2019-07-18",
      "has_results": true,
      "last_update_posted_date": "2022-06-27",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02836652"
    },
    {
      "nct_id": "NCT00345618",
      "title": "Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Embolism",
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Idrabiotaparinux sodium",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for idrabiotaparinux sodium)",
          "type": "DRUG"
        },
        {
          "name": "Avidin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for warfarin)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3202,
      "start_date": "2006-06",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345618"
    },
    {
      "nct_id": "NCT00957242",
      "title": "AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 145,
      "start_date": "2009-10",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2014-07-23",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957242"
    },
    {
      "nct_id": "NCT00781391",
      "title": "Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke",
        "Atrial Fibrillation",
        "Embolism"
      ],
      "interventions": [
        {
          "name": "warfarin tablets",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban tablets (high dose regimen-60mg)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban tablets (low dose regimen-30mg)",
          "type": "DRUG"
        },
        {
          "name": "placebo warfarin",
          "type": "DRUG"
        },
        {
          "name": "placebo edoxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 21105,
      "start_date": "2008-11",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 316,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Lake Havasu City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00781391"
    },
    {
      "nct_id": "NCT00027066",
      "title": "Warfarin Versus Aspirin Recurrent Stroke Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Active Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Active Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Aspirin placebo",
          "type": "DRUG"
        },
        {
          "name": "Warfarin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 2206,
      "start_date": "1993-06",
      "completion_date": "2001-11",
      "has_results": false,
      "last_update_posted_date": "2011-06-17",
      "last_synced_at": "2026-09-13T04:52:30.349Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027066"
    }
  ]
}